Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 19

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 19
---
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

The date of this prospectus is April 30, 2024.

TABLE OF CONTENTS

|                                     |     | Page |    |
| About this Prospectus               |     |      | ii |
| Prospectus Summary                  |     |      |  1 |
| Risk Factors                        |     |      |  5 |
| Forward-Looking                     
 Statements                          |     |      |  5 |
| Use of Proceeds                     |     |      |  6 |
| Description of Capital Stock        |     |      |  6 |
| Description of Debt Securities      |     |      |  7 |
| Description of Warrants             |     |      | 14 |
| Description of Units                |     |      | 15 |
| Plan of Distribution                |     |      | 15 |
| Legal Matters                       |     |      | 18 |
| Experts                             |     |      | 18 |
| Where You Can Find More Information |     |      | 18 |
| Incorporation by Reference          |     |      | 19 |

i

ABOUT THIS PROSPECTUS

This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
“shelf” registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings for an aggregate offering price up to $150,000,000.

This prospectus provides you with a general description of the securities that may be offered. Each time we sell securities, we will
provide one or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. Before you invest in our
securities, you should read both this prospectus and any applicable prospectus supplement together with the additional information described in the sections titled “Where You Can Find More Information” and “Incorporation by
Reference.”

We have not authorized anyone to provide you with information that is different from that contained, or incorporated by
reference, in this prospectus, any applicable prospectus supplement or in any related free writing prospectus. We take no responsibility for, and can provide